PSA and second-line therapy of hormone refractory prostate carcinoma

Urologia Internationalis

Volumn 66, Issue 3, 2001, Pages 131-134

  Serretta, Vincenzo ^a,c   Rizzo, I ^b   Contino, G ^b   Pavone, C ^a   Pomara, G ^a   Melloni, D ^a   Pavone Macaluso, M ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Ospedale Civico e Benfratelli   (Italy)

^c NONE   (Italy)

Author keywords

Hormone refractory; Prostate; Prostatic adenocarcinoma; PSA

Indexed keywords

BICALUTAMIDE; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GONADORELIN; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HORMONAL THERAPY; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0035027284     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056591     Document Type: Article

References (17)

1. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer
2. Changes in free and free-to-total prostate-specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer
3. Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials
4. The reliability of a linear analogue for evaluating pain
5. Graphic representation of pain
6. Management of relapsing disease in prostate cancer
7. Prostate-specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer
8. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer
9. Quality of life in metastatic prostate cancer among men of lower socioeconomic status: Feasibility and criterion-related validity of three measures
10. Differences in urologist and patient assessments of health-related quality of life in men with prostate cancer: Results of the capsure database
11. Quality of life and treatment of hormone-resistant metastatic prostatic cancer
12. Palliative care: Management of the patient with advanced cancer
13. Quality of life after palliative radio-therapy in patients with hormone-resistant prostate cancer: Single institution experience
14. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
15. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure
16. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument